Document Server@UHasselt >
Research publications >
Please use this identifier to cite or link to this item:
|Title: ||Phase II study of weekly 4'-epidoxorubicin in patients with metastatic adenocarcinoma of the cervix: an EORTC Gynaecological Cancer Cooperative Group study|
|Authors: ||van der Burg, M.E.L.|
|Issue Date: ||1997|
|Publisher: ||Elsevier Science Ltd.|
|Citation: ||European journal of cancer, 33(9). p. 1513-1515|
|Abstract: ||In this study 22 patients with metastatic adenocarcinoma of the cervix were treated with a weekly bolus injection of 4′-epidoxorubicin at a dose of 12 mg/m2. Seventeen patients had received prior radiotherapy, all patients were chemo-naive. Toxicity was generally absent or very mild. One patient had a complete response and 2 patients had a partial response, one was an unconfirmed partial response, giving a response rate of 14%. Six patients had stable disease. The median progression-free survival and overall survival was 2.8 months and 6.1 months, respectively. In conclusion, 4 -epidoxorubicin used at this dosage and schedule has minimal activity in metastatic adenocarcinoma of the cervix.|
|Type: ||Journal Contribution|
|Appears in Collections: ||Research publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.